Status:
COMPLETED
Sodium, Nocturnal Blood Pressure and Nocturnal Pauses in Breathing
Lead Sponsor:
Jesper Norgaard Bech
Conditions:
Sodium Imbalance
Nocturnal Blood Pressure
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
A reduction of dietary sodium intake reduces blood pressure and risk of cardiovascular disease.
Detailed Description
A reduction of dietary sodium intake reduces blood pressure and risk of cardiovascular disease. Patients with hypertension resistant of antihypertensive treatment have a high frequency of non-dipping ...
Eligibility Criteria
Inclusion
- 24h blood pressure \> 130/80 mmHg under antihypertensive treatment with three agent, one of these being diuretic. Blood pressure measurement completed after observed intake of antihypertensive medication.
- unchanged antihypertensive treatment for three months
- estimated glomerular function \>45 mL/min/1.73 m2
Exclusion
- Heart failure assessed from NYHA classification (grade 3-4)
- Presence of clinically significant peripheral edema
- In treatment for obstructive sleep apnea
- Chronic obstructive pulmonary disease (FEV1 \<50%)
- Antihypertensive therapy that can not be taken once daily
- Pregnancy or breastfeeding
- Β-albumin \<34 g / l
- U-albumin creatinine ratio\> 1000 mg / g
- INR\> 1.2 (if marevan treatment: ALAT\> 200)
- Gluten allergy (dietary guidelines are not adjusted to this group)
Key Trial Info
Start Date :
January 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06022133
Start Date
January 3 2018
End Date
March 31 2021
Last Update
September 1 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University clinic in Nephrology and hypertension, Regional Hospital Godstrup
Gødstrup, Herning, Denmark, 7400
2
Department of Medical Research and Medicine, Holstebro Regional Hospital
Holstebro, Denmark, 7500